Physician profile
Samuel Mathew
NPI 1801959705
$1,109.78
in general payments reported to CMS, 2019-2025
11 companies · $64.88 in 2025
The $64.88 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $782 · 2020: $211 · 2021: $40.16 · 2022: $11.75 · 2025: $64.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $64.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $64.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $350.15 | 2019-2020 | |
| Allergan, INC. | $214.89 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $160.10 | 2019-2020 | |
| Esperion Therapeutics, INC. | $102.92 | 2020-2021 | |
| Ardelyx, INC. | $64.88 | 2025 | Ibsrela |
| Amarin Pharma, INC. | $51.10 | 2019 | |
| Arbor Pharmaceuticals, INC. | $50.06 | 2019-2020 | |
| Lilly USA, LLC | $36.44 | 2019 | |
| Ironwood Pharmaceuticals, INC | $36.38 | 2019 | |
| Vifor Pharma, INC. | $24.44 | 2021-2022 | |
| Infobionic, INC | $18.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.